NEW YORK, NY / ACCESS Newswire / March 7, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and ...

The latest trading day saw Novo Nordisk (NVO) settling at $87.17, representing a -0.99% change from its previous close.

Apostrophe is being shut down to "simplify its (company’s) dermatology products and operations into one seamless experience," ...

My monthly update and commentary on the top dividend stock picks sourced from Barron's, March 2025 edition. Standout choices ...

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

(Reuters) - A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly (NYSE: LLY ...

Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try ...

Shares of Hims & Hers Health ( HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00.Discover the ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Bayer announces fourth-quarter results. NVO cuts cost of Wegovy for the uninsured. ABBV enters obesity space with new deal.